Clinical immunotherapy in glioma: current concepts, challenges, and future perspectives

Front Immunol. 2024 Nov 1:15:1476436. doi: 10.3389/fimmu.2024.1476436. eCollection 2024.

Abstract

Glioma is one of the common tumors in the central nervous system, and its treatment methods (surgery, radiotherapy, and chemotherapy) lack specificity and have a poor prognosis. With the development of immunology, cell biology, and genomics, tumor immunotherapy has ushered in a new era of tumor therapy, achieving significant results in other invasive cancers such as advanced melanoma and advanced non-small cell lung cancer. Currently, the clinical trials of immunotherapy in glioma are also progressing rapidly. Here, this review summarizes promising immunotherapy methods in recent years, reviews the current status of clinical trials, and discusses the challenges and prospects of glioma immunotherapy.

Keywords: CAR-T; gliomas; immune checkpoint inhibitors; immunotherapy; oncolytic virotherapy; tumor vaccines.

Publication types

  • Review

MeSH terms

  • Animals
  • Brain Neoplasms* / immunology
  • Brain Neoplasms* / therapy
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use
  • Clinical Trials as Topic
  • Glioma* / immunology
  • Glioma* / therapy
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy* / methods

Substances

  • Immune Checkpoint Inhibitors
  • Cancer Vaccines

Grants and funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.